| 摘要 |
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 7β-hydroxy-17-(3-pyridyl)-androst-4,16-diene-3-one and other androst-4,16-diene compounds substituted at the 17-position with a heterocycle moiety and at the 3- and 7-positions with a hydroxyl, ester, ether or other disclosed moiety. |
| 主权项 |
1. A compound having the structure or a salt thereof, wherein the dotted line is an optional double bond; R1 is —OH, ═O, —SH, amide, ester or ether; R2 is —OH, ═O, halogen, alkyl, ester or ether; R3 is —H, —OH, halogen, alkyl, ester or ether; R4 is a heterocycle; R5 and R6 independently are —H, —CH3, —C2H5, —C3H7, —OH, —F, —Cl, —Br or —I; R7 is —CH2—, —C(halogen)2-, —CH(α-alkyl), —CH(β-alkyl), —CH(α-OH), —CH(β-OH) or —C(alkyl)2; R9 is —CH2—, —CH(α-OH), —CH(β-OH) or —C(alkyl)2-, or R9 is ═CH— when the optional double bond is present R10A, R10B, R10C and R10D independently are —H, alkyl, —CH3, halogen, —SRPR or —ORPR and each R10A, R10B, R10C and R10D is independently in the α-configuration or the β-configuration; and RPR independently are —H or a protecting group. |
